Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.07
OTCPK:FMCQF's Cash to Debt is ranked higher than
56% of the 302 Companies
in the Global Medical Care industry.

( Industry Median: 0.19 vs. OTCPK:FMCQF: 0.07 )
OTCPK:FMCQF' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.07

Equity to Asset 0.39
OTCPK:FMCQF's Equity to Asset is ranked higher than
70% of the 303 Companies
in the Global Medical Care industry.

( Industry Median: 0.41 vs. OTCPK:FMCQF: 0.39 )
OTCPK:FMCQF' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.5
Current: 0.39

0.34
0.5
Interest Coverage 5.04
OTCPK:FMCQF's Interest Coverage is ranked higher than
69% of the 194 Companies
in the Global Medical Care industry.

( Industry Median: 5.06 vs. OTCPK:FMCQF: 5.04 )
OTCPK:FMCQF' s 10-Year Interest Coverage Range
Min: 1.6   Max: 9999.99
Current: 5.04

1.6
9999.99
F-Score: 5
Z-Score: 2.32
M-Score: -2.49
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 14.65
OTCPK:FMCQF's Operating margin (%) is ranked higher than
87% of the 305 Companies
in the Global Medical Care industry.

( Industry Median: 8.59 vs. OTCPK:FMCQF: 14.65 )
OTCPK:FMCQF' s 10-Year Operating margin (%) Range
Min: 7.8   Max: 16.51
Current: 14.65

7.8
16.51
Net-margin (%) 6.88
OTCPK:FMCQF's Net-margin (%) is ranked higher than
83% of the 305 Companies
in the Global Medical Care industry.

( Industry Median: 4.91 vs. OTCPK:FMCQF: 6.88 )
OTCPK:FMCQF' s 10-Year Net-margin (%) Range
Min: -6.47   Max: 8.6
Current: 6.88

-6.47
8.6
ROE (%) 11.46
OTCPK:FMCQF's ROE (%) is ranked higher than
79% of the 286 Companies
in the Global Medical Care industry.

( Industry Median: 9.56 vs. OTCPK:FMCQF: 11.46 )
OTCPK:FMCQF' s 10-Year ROE (%) Range
Min: -12.24   Max: 14.9
Current: 11.46

-12.24
14.9
ROA (%) 4.53
OTCPK:FMCQF's ROA (%) is ranked higher than
77% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 3.52 vs. OTCPK:FMCQF: 4.53 )
OTCPK:FMCQF' s 10-Year ROA (%) Range
Min: -4.64   Max: 6.13
Current: 4.53

-4.64
6.13
ROC (Joel Greenblatt) (%) 37.34
OTCPK:FMCQF's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 305 Companies
in the Global Medical Care industry.

( Industry Median: 18.24 vs. OTCPK:FMCQF: 37.34 )
OTCPK:FMCQF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 26.97   Max: 77.44
Current: 37.34

26.97
77.44
Revenue Growth (%) 6.10
OTCPK:FMCQF's Revenue Growth (%) is ranked higher than
74% of the 239 Companies
in the Global Medical Care industry.

( Industry Median: 6.10 vs. OTCPK:FMCQF: 6.10 )
OTCPK:FMCQF' s 10-Year Revenue Growth (%) Range
Min: -13.5   Max: 13.7
Current: 6.1

-13.5
13.7
EBITDA Growth (%) 5.10
OTCPK:FMCQF's EBITDA Growth (%) is ranked higher than
72% of the 191 Companies
in the Global Medical Care industry.

( Industry Median: 6.50 vs. OTCPK:FMCQF: 5.10 )
OTCPK:FMCQF' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 41.3
Current: 5.1

0
41.3
EPS Growth (%) 3.20
OTCPK:FMCQF's EPS Growth (%) is ranked higher than
69% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 10.90 vs. OTCPK:FMCQF: 3.20 )
OTCPK:FMCQF' s 10-Year EPS Growth (%) Range
Min: -11.1   Max: 64.1
Current: 3.2

-11.1
64.1
» OTCPK:FMCQF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with OTCPK:FMCQF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Fresenius Medical Care AG & Co. KGaA

SymbolPriceYieldDescription
FMCMF67.800.00
FME3.Germany54.200.96
0EH5.UK54.001.05
FMSPR0.001.06ADR

Ratios

vs
industry
vs
history
P/E(ttm) 22.80
FMCQF's P/E(ttm) is ranked higher than
84% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 43.60 vs. FMCQF: 22.80 )
FMCQF' s 10-Year P/E(ttm) Range
Min: 12.89   Max: 27.06
Current: 22.8

12.89
27.06
P/B 2.41
FMCQF's P/B is ranked higher than
78% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 2.96 vs. FMCQF: 2.41 )
FMCQF' s 10-Year P/B Range
Min: 1.3   Max: 4.01
Current: 2.41

1.3
4.01
P/S 1.45
FMCQF's P/S is ranked higher than
70% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 1.55 vs. FMCQF: 1.45 )
FMCQF' s 10-Year P/S Range
Min: 0.99   Max: 1.93
Current: 1.45

0.99
1.93
PFCF 24.09
FMCQF's PFCF is ranked higher than
85% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 85.90 vs. FMCQF: 24.09 )
FMCQF' s 10-Year PFCF Range
Min: 10.97   Max: 54
Current: 24.09

10.97
54
EV-to-EBIT 14.34
FMCQF's EV-to-EBIT is ranked higher than
86% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 22.71 vs. FMCQF: 14.34 )
FMCQF' s 10-Year EV-to-EBIT Range
Min: 7.3   Max: 50.8
Current: 14.34

7.3
50.8
PEG 19.00
FMCQF's PEG is ranked higher than
83% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. FMCQF: 19.00 )
FMCQF' s 10-Year PEG Range
Min: 0.75   Max: 17.36
Current: 19

0.75
17.36
Shiller P/E 23.13
FMCQF's Shiller P/E is ranked higher than
90% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 1193.86 vs. FMCQF: 23.13 )
FMCQF' s 10-Year Shiller P/E Range
Min: 17.26   Max: 33.57
Current: 23.13

17.26
33.57
Current Ratio 1.50
FMCQF's Current Ratio is ranked higher than
77% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 1.34 vs. FMCQF: 1.50 )
FMCQF' s 10-Year Current Ratio Range
Min: 0.8   Max: 1.93
Current: 1.5

0.8
1.93
Quick Ratio 1.23
FMCQF's Quick Ratio is ranked higher than
72% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 1.21 vs. FMCQF: 1.23 )
FMCQF' s 10-Year Quick Ratio Range
Min: 0.7   Max: 1.61
Current: 1.23

0.7
1.61

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.43
FMCQF's Dividend Yield is ranked lower than
51% of the 178 Companies
in the Global Medical Care industry.

( Industry Median: 1.47 vs. FMCQF: 1.43 )
FMCQF' s 10-Year Dividend Yield Range
Min: 1.1   Max: 2.05
Current: 1.43

1.1
2.05
Dividend Payout 0.30
FMCQF's Dividend Payout is ranked higher than
92% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. FMCQF: 0.30 )
FMCQF' s 10-Year Dividend Payout Range
Min: 0.91   Max: 1.36
Current: 0.3

0.91
1.36
Dividend growth (3y) 8.60
FMCQF's Dividend growth (3y) is ranked higher than
77% of the 120 Companies
in the Global Medical Care industry.

( Industry Median: 8.60 vs. FMCQF: 8.60 )
FMCQF' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 8.6
Current: 8.6

0
8.6
Yield on cost (5-Year) 1.87
FMCQF's Yield on cost (5-Year) is ranked higher than
50% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 2.11 vs. FMCQF: 1.87 )
FMCQF' s 10-Year Yield on cost (5-Year) Range
Min: 1.47   Max: 2.74
Current: 1.87

1.47
2.74
Share Buyback Rate -0.50
FMCQF's Share Buyback Rate is ranked higher than
82% of the 194 Companies
in the Global Medical Care industry.

( Industry Median: -1.40 vs. FMCQF: -0.50 )
FMCQF' s 10-Year Share Buyback Rate Range
Min: 0.6   Max: -26.6
Current: -0.5

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.34
FMCQF's Price/DCF (Projected) is ranked higher than
84% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 4.19 vs. FMCQF: 1.34 )
FMCQF' s 10-Year Price/DCF (Projected) Range
Min: 0.8   Max: 7.23
Current: 1.34

0.8
7.23
Price/Median PS Value 1.03
FMCQF's Price/Median PS Value is ranked higher than
83% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 1.26 vs. FMCQF: 1.03 )
FMCQF' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 1.74
Current: 1.03

0.23
1.74
Price/Peter Lynch Fair Value 2.39
FMCQF's Price/Peter Lynch Fair Value is ranked higher than
90% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. FMCQF: 2.39 )
FMCQF' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.85   Max: 4.68
Current: 2.39

0.85
4.68
Earnings Yield (Greenblatt) 7.00
FMCQF's Earnings Yield (Greenblatt) is ranked higher than
84% of the 302 Companies
in the Global Medical Care industry.

( Industry Median: 4.80 vs. FMCQF: 7.00 )
FMCQF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2   Max: 13.7
Current: 7

2
13.7
Forward Rate of Return (Yacktman) 9.13
FMCQF's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 246 Companies
in the Global Medical Care industry.

( Industry Median: 9.05 vs. FMCQF: 9.13 )
FMCQF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -3.6   Max: 20.2
Current: 9.13

-3.6
20.2

Business Description

Industry: Health Care Providers » Medical Care
Compare: » details
Traded in other countries:0H9X.UK, FMS.USA, FMEA.Germany, FME.Germany, FMEN.Germany, FME3.Germany, 0EH5.UK, 0QJE.UK
Fresenius Medical Care AG & Co. KGaA was incorporated on August 5, 1996. It is a kidney dialysis company, operating in both the field of dialysis products and the field of dialysis services. The Company's dialysis business is vertically integrated, providing dialysis treatment at its own dialysis clinics and supplying these clinics with a range of products. In addition, to providing dialysis treatments, includes pharmacy services and vascular access surgery services. It sells dialysis products to other dialysis service providers. It also develops and manufactures equipment, systems and disposable products, which it sells to customers in over 120 countries. It offers life-maintaining and life-saving dialysis services and products in a market which is characterized by a favorable demographic development. It provides expanded and enhanced patient services, including renal pharmaceutical products and laboratory services, to both its own clinics and those of third parties. The Company's clinics also provide services for home dialysis patients, the majority of whom receive peritoneal dialysis treatment. It also provides dialysis services under contract to hospitals in the U.S. on an 'as needed' basis for hospitalized ESRD patients and for patients suffering from acute kidney failure. The Company provides laboratory testing and marketing services in the U.S. through Spectra Laboratories (Spectra). Spectra provides blood, urine and other bodily fluid testing services to determine the appropriate individual dialysis therapy for a patient and to assist physicians in determining whether a dialysis patient's therapy regimen, diet and medicines remain optimal. The Company's main trademarks are the name 'Fresenius' and the 'F' logo'. The Company's competitors in the sale of hemodialysis and peritoneal dialysis products include, Baxter International Inc., Asahi Kasei Kuraray Medical Co. Ltd., Bellco S.r.l., B. Braun Melsungen AG, Nipro Corporation Ltd., Nikkiso Co., Ltd., Terumo Corporation, Kawasumi Laboratories Inc., Fuso Pharmaceuticals Industries Ltd., and Toray Industries, Inc. The Company's operations are subject to extensive governmental regulation by virtually every country in which it operates, including the U.S., at the federal, state and local levels.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK